PPBT Stock Price and Chart — NASDAQ:PPBT — TradingView

About Purple Biotech Ltd.

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Check out other big names from the same industry as PPBT.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy